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Background: The mechanisms responsible for chemoresistance in patients with refractory classical Hodgkin
lymphoma (CHL) are unknown. ATP-binding cassette (ABC) transporters confer multidrug resistance in various
cancers and ABCC1 overexpression has been shown to contribute to drug resistance in the CHL cell line, KMH2.
Findings: We analyzed for expression of five ABC transporters ABCB1, ABCC1, ABCC2, ABCC3 and ABCG2 using
immunohistochemistry in 103 pre-treatment tumor specimens obtained from patients with CHL. All patients
received first-line standard chemotherapy with doxorubicin (AdriamycinW), bleomycin, vinblastine, and dacarbazine
(ABVD) or equivalent regimens. ABCC1 was expressed in Hodgkin and Reed-Sternberg (HRS) cells in 16 of 82 cases
(19.5%) and ABCG2 was expressed by HRS cells in 25 of 77 cases (32.5%). All tumors were negative for ABCB1,
ABCC2 and ABCC3. ABCC1 expression was associated with refractory disease (p = 0.01) and was marginally
associated with poorer failure-free survival (p = 0.06). Multivariate analysis after adjusting for hemoglobin and
albumin levels and age showed that patients with CHL with HRS cells positive for ABCC1 had a higher risk of not
responding to treatment (HR = 2.84, 95%, CI: 1.12-7.19 p = 0.028).
Conclusions: Expression of ABCC1 by HRS cells in CHL patients predicts a higher risk of treatment failure and is
marginally associated with poorer failure-free survival using standard frontline chemotherapy regimens.
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Classical Hodgkin lymphoma (CHL) is largely a curable
disease using the widely accepted current standard first-
line chemotherapy regimen of doxorubicin (AdriamycinW),
bleomycin, vinblastine, and dacarbazine (ABVD) or equiva-
lent regimens, with or without consolidation radiother-
apy [1]. However, approximately 20% of patients with
CHL do not respond following first-line therapy, or re-
lapse quickly, and require additional treatment with
salvage chemotherapy with or without stem cell trans-
plantation [1,2]. A drawback to the currently used* Correspondence: fvegava@mdanderson.org
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reproduction in any medium, provided the ortreatment modalities is their association with po-
tentially life-threatening toxicities. In addition, patients
cured of CHL have an increased lifetime relative risk of
death from non CHL-related causes, presumably attrib-
utable, at least in part, to therapy [3]. Thus, investigators
continue to actively pursue novel prognostic biomarkers
and therapeutic options in CHL patients with the goals
of maintaining or improving survival rates as well as
minimizing adverse side effects in patients with favor-
able prognosis [2]. Recently, a number of biomarkers
expressed by Hodgkin and Reed-Sternberg (HRS) cells
as assessed in tissue samples have been proposed as
being useful for predicting prognosis in CHL patients [4].
These molecules include matrix metalloproteinase 11
(MMP11), CD20, Bcl2, MAL, HLA class II and Ki67,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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such as tumor-associated macrophages or subsets of
tumor-infiltrating lymphocytes, including FOXP3+
regulatory T cells (Tregs) and granzyme B + T/NK cells
[5-10].
The development of chemotherapy resistance by can-
cer cells is multifactorial [11]. ATP binding cassette
(ABC) transporters comprise a ubiquitous family of
transmembrane proteins that play a physiologic role in
the transport of substrates across cytoplasmic mem-
branes. ABC transporters also play a role in multidrug
resistance (MDR) in multiple tumor types by using ATP
as an energy source to actively expel drug substrates
from the tumor cell cytoplasm into the extracellular
space [12]. Expression of ABC transporters has been
shown to correlate with response to therapy and progno-
sis in several hematological malignancies including acute
myeloid leukemia and diffuse large B-cell lymphoma
[13-15]. Although the clinical impact of ABC transpor-
ters in CHL has not been reported, several drugs used to
treat CHL are known substrates of various ABC trans-
porters [11,16], including doxorubicin (a substrate for
ABCB1, ABCC1, ABCC2, ABCC3, ABCG2), vinblastine
(a substrate for ABCB1 and ABCC1) and vincristine
(a substrate for ABCC1).
Steidl et al. recently showed overexpression of the
ABC transporter, ABCC1 (also known as multidrug re-
sistance protein 1 - MRP1) in the therapy-resistant
CHL-derived cell line, KMH2 [17]. They further showed
that increased sensitivity of KMH2 cells to AdriamycinW
toxicity by siRNA silencing of ABCC1. Prompted by this
finding, we assessed for expression of five ABC transpor-
ters, ABCG2, ABCB1, ABCC1, ABCC2, and ABCC3, in
untreated CHL tumor specimens. We also investigated
the potential prognostic value of expression of these
ABC transporters in CHL.
Design and methods
The overall clinical and pathologic features of the study
group are summarized in Table 1. The group included
103 patients with CHL who were seen at our hospital
and treated with standard front-line chemotherapy using
ABVD (36 patients) or equivalent regimens including
CVPP/ABDIC (cyclophosphamide, vinblastine, procarba-
zine, and prednisone/AdriamycinW, bleomycin, dacarba-
zine, lomustine and prednisone) (20 patients), MOPP/
ABVD (mechlorethamine, vincristine, prednisone, pro-
carbazine/AdriamycinW, bleomycin, vinblastine, dacarba-
zine) (3 patients) or NOVP (NovantroneW, vincristine,
vinblastine, and prednisone) (44 patients) with and with-
out radiotherapy. Additionally, 10 patients underwent
allogeneic stem cell transplantation as salvage therapy.
We analyzed for expression of five ABC transporters -
ABCG2, ABCB1, ABCC1, ABCC2, and ABCC3 - in pre-treatment samples of CHL using (see Table 2). immunohis-
tochemical methods and tissue microarrays (TMA). Seven
TMAs were constructed using triplicate cores prepared
from routinely processed paraffin-embedded tissue speci-
mens as described previously [18]. Additionally, we were
able to retrieve tissue blocks and use routine histologic sec-
tions to analyze ABCC1 and ABCG2 expression in 13 and
5 CHL tumors, respectively, that suffered tissue loss on the
TMAs. This work was performed under an approved IRB
protocol in our institution. For each marker, a tumor was
considered positive when HRS cells were positive. For
these proteins expression was all or none. In other words,
in positive cases virtually all HRS cells were positive.
Fisher’s exact test was used to evaluate the association
of clinical response with categorical variables. The
Kaplan-Meier method and log rank test were used for
survival analysis. The following variables were evaluated
in univariate analysis: disease stage (IV vs. I/II/III),
Table 2 Antibodies used for immunohistochemistry
Antibody
Common Name
Systematic Name Clone Manufacturer Antibody Conc. Normal Tissue
Control
ABCG2 MXR, BCRP, ABC-P Mouse monoclonal BXP-21 Santa Cruz Biotechnology Inc.
Santa Cruz, CA
1:40 Placenta
MDR1 ABCB1, PGP Mouse monoclonal G-1 Santa Cruz Biotechnology Inc.
Santa Cruz, CA
1:100 Liver
MRP1 ABCC1 Mouse monoclonal QCRL-1 Santa Cruz Biotechnology Inc.
Santa Cruz, CA
1:50 Stomach
MRP2 ABCC2 Mouse monoclonal M2 III-6 Abcam Inc. Cambridge MA 1:50 Liver
MRP3 ABCC3 Mouse monoclonal DTX1 Abcam Inc. Cambridge MA 1:50 Liver
Greaves et al. Journal of Hematology & Oncology 2012, 5:47 Page 3 of 6
http://www.jhoonline.org/content/5/1/47chemotherapy (ABVD, CVP or NOVP), radiation ther-
apy (yes and no), bone marrow metastasis (positive
and negative), serum albumin (< and > 40 g/L), WBC
(< and ≥ 15,000 per mm3), hemoglobin (< or > 105 g/L),
lymphocytes (< and ≥ 600 per mm3 or < and≥ 8% of
WBC), gender, International Prognostic Score (IPS)
(< and ≥ 3), and age (< and ≥ 45 years). Multivariate
Cox proportional hazards models including variables
with p value < 0.15 in univariate analysis were fitted to
evaluate the association of survival with demographic
and clinical factors. Variables with p values < 0.05 were
considered statistically significant. S plus software 8.04
(TIBCO software Inc., Palo Alto, CA) and SAS software
(SAS Institute Inc., Cary, NC) were used for statistical
analysis.
Results and discussion
We tested for expression of five ABC transporters in un-
treated tumor specimens of CHL. These transporters use
as substrates chemotherapeutic agents commonly used
to treat CHL patients including AdriamycinW, vincristine,
vinblastine, and mitoxantrone, among others [11].A B
D E
Figure 1 Immunohistochemical expression of ABC proteins in positiv
(positive control). B. CHL with negative expression of ABCC1 by HRS cells; s
for cytoplasmic expression of ABCC1. D. Placenta with ABCG2 expression in
for ABCG2; endothelial cells and scattered inflammatory cells are positive. FABCG2 and ABCC1 were expressed by HRS cells in a
subset of CHL tumors (Figure 1). Sixteen of 82 (19.5%)
CHL were positive for ABCC1 and 25 of 77 (32.5%) CHL
were positive for ABCG2 (a subset of tissue cores was
variably lost on the TMAs). Both ABCC1 and ABCG2
showed cytoplasmic expression in all HRS cells
(Figures 1C and F). There was no substantial difference
in the intensity of expression of ABCC1 or ABCG2 by
HRS cells. Variable, non-specific staining for ABCC1 and
ABCG2 was also observed inconsistently in a small sub-
set of background inflammatory cells, including plasma
cells, lymphocytes, eosinophils and histiocytes, in both
HRS-positive and HRS-negative cases. There was no ex-
pression of ABCB1, ABCC2 and ABCC3 by HRS cells in
any case analyzed (Figures 2B, D and E). Consistent ex-
pression of both ABCC1 and ABCG2 in endothelial cells
was used as an internal positive control for immunohis-
tochemical staining (see Figures 2B and D).
We sought to determine if there was an association
between expression of either ABCC1 or ABCG2 and
clinical endpoints, such as response to treatment (refrac-
tory disease vs non-refractory disease), overall survivalC
F
e controls and CHL tumors. A. ABCC1 is expressed by gastric glands
cattered histiocytes are weakly positive. C. CHL with HRS cells positive
trophoblastic cells (positive control). E. CHL with HRS cells negative




Figure 2 Immunohistochemical expression of ABC proteins in positive controls and call tumors. A. Canalicular staining pattern of MDR1 in
liver (positive control). B. MDR1 is not expressed in the HRS cells of CHL (white arrows); endothelial cells are positive (black arrow). C. Canalicular
staining pattern of ABCC2 in liver (positive control). D. HRS cells are negative for ABCC2; endothelial cells and scattered lymphocytes are positive.
E. Hepatocytes show cytoplasmic expression of ABCC3 (positive control). F. HRS cells are negative for ABCC3.
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http://www.jhoonline.org/content/5/1/47(OS), and failure free survival (FFS). Admittedly, the
numbers are relatively small hampering this analysis. In
this study FFS was defined as lack of disease progression,
recurrence or death. Refractory disease was defined as
patients with only a partial response to therapy, or re-
currence within the first 18 months of initial therapy
[19,20]. The log rank test showed that ABCC1 expres-
sion was marginally associated with FFS: 19 of 66
ABCC1 negative patients and 7 of the ABCC1 positive
patients experienced treatment failure. The estimated 5-
year FFS probabilities were 80.7% (95% CI:71.4% -91.2%)
for ABCC1 negative group and 68.8% (95% CI:49.4%-
95.7%) for the ABCC1 positive group, respectively
(p = 0.06, Figure 3). Multivariate analysis after adjusting






















P value = 0.06
Figure 3 ABCC1 expression was marginally associated with failure-frelevel suggested that ABCC1 expression was an inde-
pendent prognostic marker for FFS. Patients with
ABCC1 expression had a higher risk of treatment failure
than patients without ABCC1 expression (HR=2.88,
95% CI: 1.18-7.01, p = 0.02, Table 3). Fisher’s exact test
suggested that ABCC1 expression was also associated
with initial response to treatment (primary refractory vs
non-primary refractory). Six of 16 patients (37.5%) with
ABCC1 expression versus 6 of 66 patients (9.1%) without
ABCC1 expression were primary refractory (p = 0.01).
This finding supports the results of Steidl and colleagues
in the KMH2 cell line [17] and suggests that expression
of ABCC1 may contribute to primary drug resistance in
CHL. Three of 16 patients with ABCC1 positive tumors




e survival (p = 0.06).
Table 3 Multivariate analysis to evaluate the association
between FFS and ABCC1
HR (95% CI) P value
ABCC1 Positive vs. negative 2.84 (1.12, 7.19) 0.028
Albumin <4 vs. > 4 1.59 (0.70, 3.63) 0.27
Age >= 45 vs. <45 2.14 (1.53, 0.13) 0.13
*Please note: HB (<10.5 vs. > 10.5) was included in the model as a stratification
factor since the proportional hazards assumption for it was not held.
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the ABCC1 positive and negative groups (p = 0.74).
ABCC1 expression was not significantly associated with
other clinical parameters (Table 4). Fisher’s exact test
was also used to compare the patient characteristics be-
tween ABCC1 known and ABCC1 unknown groups
(Additional file 1: Table S1). More patients 45 years of
age or older had ABCC1 measurements (17/28, 60.7%)
(p value =0.0036). A majority of patients who received
CVPP treatment had ABCC1 measurements (18/20,
90%) (p value = 0.049). No other significant difference









Bone marrow disease No 62
Yes 3
Stage IV disease No 53
Yes 13
Hemoglobin ≥105 g/l 58
< 105 g/l 8
Albumin ≥ 40 g/l 35
< 40 g/l 23
WBC <15,000 per mm3 62
≥15,000 per mm3 4
Lymphocytes < 600 per mm3 52
≥ 600 per mm3 11
Age ≥45 < 45 years 51




≥3 14Expression of ABCG2 by HRS cells was not signifi-
cantly associated with OS, FFS or initial response to
treatment. The lack of association of ABCG2 expression
with treatment refractoriness, in contrast to ABCC1, is
not fully explained, and relatively little is known about
the differential substrate profiles of these two proteins.
However, some authors have shown that certain drugs
that are poor ABCC1 substrates, such as mitoxantrone
(a type 2 topoisomerase inhibitor), are associated with
overexpression of ABCG2 in vitro [11,21], and such dif-
ferences may have played a role in the discordant impact
of these two proteins on therapy resistance in this pa-
tient cohort.
Conclusions
In summary, ABCC1 and ABCG2 are expressed by HRS
cells in a subset of CHL tumors. Univariate and multi-
variate analyses showed that expression of ABCC1 by
HRS cells is associated with an increased risk of tumor
progression, treatment resistance or death in CHL
patients. Our findings corroborate those published byn ABCC1 and other clinical factors
1 Negative ABCC1 Positive Fisher's ExactTest (2-Tail)
(79.6%) 10 (20.4%) .5227
(88%) 3 (12%)
(76.9%) 6 (23.1%) .8762
(83.3%) 3 (16.7%)
(81.6%) 7 (18.4%)
(89.5%) 2 (10.5%) .3329
(77.6%) 13 (22.4%)
(79.5%) 16 (20.5%) 1.000
(100%) 0 (0%)
(80.3%) 13 (19.7%) 1.000
(81.3%) 3 (18.8%)
(79.5%) 15 (20.5%) .6811
(88.9%) 1 (11.1%)
(79.5%) 9 (20.5%) 1.000
(82.1%) 5 (17.9%)
(79.5%) 16 (20.5%) .5814
(100%) 0 (0%)
(80%) 13 (20%) 1.000
(78.6%) 3 (21.4%)
(78.5%) 14 (21.5%) .5028
(88.2%) 2 (11.8%)
(76.5%) 8 (23.5%) .5731
(83.3%) 8 (16.7%)
(77.3%) 15 (22.7%) .2811
(93.3%) 1 (6.7%)
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provide evidence that expression of ABCC1 may be use-
ful as an indicator of poorer FFS or failure to respond to
therapy in CHL patients who are treated with standard
regimens. Additionally, ABCC1 may serve as a potential
target for therapeutic intervention by increasing suscep-
tibility to chemotherapy.
Additional file
Additional file 1: Table S1. Fisher’s exact test to compare clinical
factors between ABCC1 unknown and ABCC1 known groups.
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